Return to AIDS/HIV Alert Section
Researchers from National Chung Cheng University, Department of Chemical Engineering publish new studies and findings in the area of gene therapy
September 3rd, 2007
2007 SEP 3 -- A new study, "Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles," is now available. According to recent research from Taiwan, "Permeability of the anti-human immunodeficiency virus (HIV) agents, including stavudine (D4T), delavirdine (DLV), and saquinavir (SQV), across the in vitro blood-brain barrier (BBB) was studied. Here, the anti-HIV agents were incorporated with polybutylcyanoacrylate (PBCA) nanoparticles (NPs), methylmethacrylate-sulfopropylmethacrylate (MMA-SPM) NPs, and solid lipid nanoparticles (SLNs)."
"Transport of the anti-HIV agents across BBB is a key factor in their applications to the therapy of the acquired immunodeficiency syndrome (AIDS). Experimental results revealed that the drug order of the loading efficiency (LE) on PBCA and MMA-SPM was D4T >DLV >SQV. For the entrapment efficiency (EE) in SLNs, this order was reversed. Also, LE of D4T on MMA-SPM was larger than that on PBCA; however, the reverse was true for DLV and SQV. As the particle size increased, LE decreased and EE increased. For a fixed drug carrier, an increase in the particle size yielded a decrease in the BBB permeability coefficient of the anti-HIV agents. Moreover, enhancement in the BBB permeability was on the carrier order of PBCA >MMA-SPM >SLNs for D4T, and for DLV and SQV, the order became PBCA >SLNs >MMA-SPM," wrote Y.C. Kuo and colleagues, National Chung Cheng University, Department of Chemical Engineering.
The researchers concluded: "PBCA, MMA-SPM, and SLNs were efficacious carriers of D4T, DLV, and SQV to meliorate BBB permeability by 3-16 folds, indicating the clinical potential of the present NP formulations for the AIDS treatment."
Kuo and colleagues published their study in International Journal of Pharmaceutics (Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. International Journal of Pharmaceutics, 2007;340(1-2):143-52).
For additional information, contact Y.C. Kuo, National Chung Cheng University, Dept. of Chemical Engineering, Chia-Yi 62102, Taiwan, ROC.
Publisher contact information for the International Journal of Pharmaceutics is: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.
Keywords: Taiwan, AIDS, Acquired Immunodeficiency Syndrome, Anti-Infectives, Biotechnology, Delavirdine, Drugs, Gene Therapy, Genetics, Genomics, HIV, Human Immunodeficiency Virus, Immunology, Nanoparticle, Nanotechnology, Nonnucleoside Reverse Transcriptase Inhibitor, Nucleoside Reverse Transcriptase Inhibitor, Pharmaceuticals, Protease Inhibitor, Saquinavir, Stavudine, Treatment, Virology.
This article was prepared by Anti-Infectives Week editors from staff and other reports. Copyright 2007, Anti-Infectives Week via NewsRx.com.
Return to AIDS/HIV Alert Section
|
|
Advertisement |
|
